LivaNova PLC (LIVN) Stock
Key stats
- Market cap
- $5.01B
- Price / Earnings ratio
- 25.6x
- EPS (TTM)
- $3.57
- Volume
- Loading
- 52-week high
- $99.38
- 52-week low
- $51.11
Source: third-party data provider, as of November 13, 2026
Compare with LIVN
Recent news
Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
LIVN
LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November
LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November
LIVN
LivaNova to Announce Third-Quarter 2026 Results
LivaNova to Announce Third-Quarter 2026 Results
LIVN
LivaNova Director Sells 1,650 Shares for $131,500
LivaNova Director Sells 1,650 Shares for $131,500
LIVNNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 65.87
- MACD 12/26/9
- 3.54
- EMA 9 of MACD
- 2.43
- MACD histogram
- 1.11
- SMA 50
- $79.96
- Price above SMA 50
- EMA 50
- $81.42
- Price above EMA 50
- SMA 200
- $73.92
- Price above SMA 200
- EMA 200
- $73.69
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.99 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
LIVNLivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November
LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November
LIVNLivaNova to Announce Third-Quarter 2026 Results
LivaNova to Announce Third-Quarter 2026 Results
LIVNLivaNova Director Sells 1,650 Shares for $131,500
LivaNova Director Sells 1,650 Shares for $131,500
LIVN
LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
LIVN
LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised
LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised
LIVN
LivaNova Q2 Earnings Call Highlights
LivaNova Q2 Earnings Call Highlights
LIVN
LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say
LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say
LIVN
LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?
LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?
LIVN
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
LIVNNews tone: automated (AI) classification of the article's content, not a price prediction.
About LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Vladimir A. Makatsaria | CEO & Director | 1973 |
| Mr. Alex Shvartsburg C.M.A. | Chief Financial Officer | 1970 |
| Ms. Natalia Sergeyevna Kozmina | Chief Human Resources Officer | 1971 |
| Mr. Ahmet Tezel Ph.D. | Chief Innovation Officer | 1975 |
| Ms. Lindsey Little | VP & Chief Accounting Officer | — |
| Briana Gotlin | Vice President of Investor Relations | — |
| Ms. Anne M. Liddy | Chief Legal Officer | 1976 |
| Deanna Wilke | Vice President of Corporate Communications | — |
| Mr. Philip Kowalczyk | Chief Strategy & Corporate Development Officer | — |
| Mr. Paul R. Buckman | President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement | 1956 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 65.87
- MACD 12/26/9
- 3.54
- EMA 9 of MACD
- 2.43
- MACD histogram
- 1.11
- SMA 50
- $79.96
- Price above SMA 50
- EMA 50
- $81.42
- Price above EMA 50
- SMA 200
- $73.92
- Price above SMA 200
- EMA 200
- $73.69
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $90.00
- Average
- $108.25
- High
- $120.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -5.5 | +8.5 | ||||||||||
| 2022 | -13.7 | +4.5 | +5.8 | -9.5 | -11.8 | -7.9 | +0.6 | -11.2 | -7.2 | -7.3 | +18.4 | -1.1 |
| 2023 | +1.8 | -15.1 | -6.1 | +12.3 | -7.6 | +12.8 | +14.7 | -5.1 | -5.3 | -6.9 | -10.4 | +12.7 |
| 2024 | -3.7 | +10.9 | +1.3 | +1.1 | -2.5 | -8.9 | -9.3 | +4.3 | +6.0 | -1.9 | +2.7 | -11.4 |
| 2025 | +7.1 | -13.4 | -5.8 | -5.2 | +17.6 | +3.7 | -7.8 | +37.1 | -8.0 | +4.0 | +21.4 | -2.5 |
| 2026 | +8.4 | +5.8 | -9.5 | -7.0 | +21.0 | +11.4 | -2.8 | -3.2 | -4.6 | +5.7 | +13.4 |
